Recent

% | $
Quotes you view appear here for quick access.

Pharmacyclics, Inc. Message Board

  • waithamcross waithamcross Jun 4, 2012 1:43 PM Flag

    material update in amsterdamn mid june

    Pharmacyclics plans to issue a material update on the ibrutinib clinical development program and its results in a press release after the EHA oral presentations.
    Oral Presentation at EHA, Amsterdam, The Netherlands (June 14-17, 2012)
    Date/Time: Saturday, June 16, 2012; 8:00 AM – 8:15 AM CET
    Location: Elicium 1
    Abstract # 1970: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) is Highly Active and Tolerable in Relapsed or Refractory and Treatment Naive Chronic Lymphocytic Leukemia Patients, Updated Results of a Phase Ib/II Study.
    Dr. Susan M. O'Brien et al. MD Anderson Cancer Center, Houston, Texas.
    Oral Presentation at EHA, Amsterdam, The Netherlands (June 14-17, 2012)
    Date/Time: Saturday, June 16, 2012; 8:15 AM – 8:30 AM CET
    Location: Elicium 1
    Abstract # 1590: Combination of the Bruton's tyrosine kinase inhibitor PCI-32765 with bendamustine/rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: Interim results of a phase Ib/II study.
    Dr. Jennifer Brown et al. Dana-Farber Cancer Institute, Boston, Massachusetts.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
PCYC
257.100.00(0.00%)Apr 23 3:59 PMEDT